Eagle Asset Management Inc. raised its position in shares of Sanofi SA (NYSE:SNY) by 66.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,807 shares of the company’s stock after buying an additional 4,302 shares during the quarter. Eagle Asset Management Inc.’s holdings in Sanofi were worth $537,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Parallel Advisors LLC raised its position in shares of Sanofi by 42.5% during the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares during the period. YorkBridge Wealth Partners LLC raised its position in shares of Sanofi by 33.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after purchasing an additional 776 shares during the period. Bronfman E.L. Rothschild L.P. raised its position in shares of Sanofi by 142.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after purchasing an additional 2,098 shares during the period. Toronto Dominion Bank raised its position in shares of Sanofi by 4.6% during the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after purchasing an additional 180 shares during the period. Finally, Mraz Amerine & Associates Inc. acquired a new stake in shares of Sanofi during the 3rd quarter worth approximately $204,000. Hedge funds and other institutional investors own 9.09% of the company’s stock.
Sanofi SA (NYSE SNY) traded down $0.34 on Thursday, reaching $43.17. The company had a trading volume of 1,495,000 shares, compared to its average volume of 1,502,720. Sanofi SA has a 12-month low of $38.45 and a 12-month high of $50.65. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. The firm has a market cap of $109,710.81, a PE ratio of 13.73, a P/E/G ratio of 2.40 and a beta of 0.86.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi SA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi SA and related companies.